Modulation of smad3 expression
OwnerNicholas M. Dean, J. Gordon Foulkes +3inventors
InventorsNicholas M. Dean, J. Gordon Foulkes, Susan M. Freier, C. Frank Bennett, William A. Gaarde
Life of this patent
Estimating the term…
Abstract
Provided are compounds capable of inhibiting SMAD3 and compositions containing same as well as methods using such compounds for treating fibrosis and scarring.
Claims31
A compound comprising an oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8 contiguous nucleobases of a sequence recited in SEQ ID NOs:
- 4-156, wherein each nucleoside is linked to any immediately adjacent nucleoside by an internucleoside linkage, and wherein the nucleobase sequence of the oligonucleotide is at least 90% complementary to SEQ ID NO:
- 1 or 2.
A compound comprising an oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising a portion which consists of at least 8 contiguous nucleobases complementary to an equal-length portion of nucleotides 297-713, 294-363, 294-313, 344-363, 357-387, 388-425, 418-636, 478-520, 617-636, 632-713, 761-861, 842-861, 875-921, 882-921, 954-1064, 959-1005, 1127-1173, 1144-1168, 1178-1311, 1178-1209, 1178-1202, 1204-1249, 1240-1311, 1274-1293, 1368-1387, 1390-1428, 1432-1607, 1432-1511, 1487-1607, 1487-1511, 1512-1531, 1522-1575, 1522-1569, 1573-1592, 1588-1607, 1639-1789, 1639-1658, 1649-1673, 1649-1668, 1664-1758, 1688-1758, 1688-1753, 1760-1789, 1760-1779, 1770-1789, 1822-1841, 1936-1960, 1936-1955, 2179-2225, 2179-2198, 2199-2225, 2199-2220, 2306-2325, 2404-2514, 2404-2428, 2454-2499, or 2495-2514 of SEQ ID NO:
- 1, and wherein the nucleobase sequence of the oligonucleotide is at least 90% complementary to SEQ ID NO:
- 1 or 2.
4-10. (canceled)
13-15. (canceled)
21-22. (canceled)
33-34. (canceled)
36-40. (canceled)
45-51. (canceled)
Dependencies are inferred from the claim text.